Research Reports

MIMI gained +34% on 18.5M volume with no identifiable news catalyst. Mint Incorporation is a Cayman Islands-registered company that was formerly known as Golden Star Acquisition Corp — a SPAC that merged or transitioned. TTM revenue of $2.92M (declining 31% YoY) with $330K gross profit (11.3% margin) and ($2.65M) operating loss. The company's business is unclear — Cayman Islands registration with limited disclosure. Revenue has declined from $4.38M (FY2024) to $2.92M. Previously surged from $2 to $4+ in late June. Recurring scanner name with no identifiable catalyst for any move. Avoid.

LGPS gained +37% on continued momentum from a special cash dividend (declared May 15, paid recently, causing a +64% after-hours spike two weeks ago). LogProstyle is a Japanese holding company that owns a real estate renovation and resale business. Revenue of ¥22,221 (FY2026) — these are likely in thousands of yen, meaning roughly $150K in USD equivalent. Operating income of ¥1,572. The financials are tiny and the company is a Japanese nano cap on NYSE American with limited English-language disclosure. The special dividend is a one-time event, not a sustainable return. The +37% move today has no new catalyst — it's momentum chasing a dividend that was already announced and paid. Avoid.

PLSM gained +75% on continued momentum from the Ouma Health partnership (home ultrasound for virtual maternity care) announced June 24 that sent the stock up 200%+. Pulsenmore is an Israeli medical device company making portable home ultrasound devices (Pulsenmore ES, FC) that connect to smartphones for remote clinical consultation. Revenue of $40.02M (314% YoY growth) with 84.2% gross margin — the growth is real. But $28.52M SG&A + $17.35M R&D = $45.87M OpEx, generating ($13M) operating loss. The Ouma Health partnership expands U.S. maternal health market access. Israeli nano caps carry governance risk. The stock already surged 200%+ three weeks ago and is now pumping again. Neutral — real technology and real growth, but overextended after two massive pumps in three weeks.

QTTB surged +72% on positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart (ADX-914) in severe/very severe alopecia areata. Eight patients showed durable or further hair growth at maintenance entry, supporting a maintenance dosing regimen. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function. The drug has FDA Fast Track designation for alopecia areata. Q32 Bio also has ADX-097 (anti-factor C1s) for complement-mediated diseases. Revenue is zero (clinical-stage), with ($32.33M) annual operating loss ($17M SG&A + $15.25M R&D). Cash position provides runway. The alopecia areata market is large and growing — Pfizer's ritlecitinib (Litfulo) and Eli Lilly's baricitinib (Olumiant) have validated the target. Bempikibart's differentiated mechanism (IL-7Rα vs JAK inhibition) could offer advantages. Speculative Buy — positive Phase 2a data with FDA Fast Track.

AGEN surged +58% on an $85M private placement with potential for an additional $255M if warrants are fully exercised. Agenus is a well-established immuno-oncology company with $123.87M TTM revenue (24% YoY growth) from its royalty-bearing Shingrix vaccine adjuvant and antibody discovery partnerships. The core pipeline centers on botensilimab (anti-CTLA-4) + balstilimab (anti-PD-1) combination therapy, with new AI-driven retrospective data from Noetik's TARIO-2 model showing tumor microenvironment patterns linked to clinical outcomes in solid tumors. ASCO data, private placement capital, and growing revenue create a strong setup. But the company remains unprofitable ($115M annual OpEx) and the botensilimab program needs Phase 3 confirmation. Speculative Buy — real oncology platform with funding, revenue, and data momentum.

JLHL gained +22% on 371K volume with no identifiable news catalyst. Julong Holding is a Chinese financial services company (securities, investment consulting, fund management) that grew revenue from $66.54M (FY2022) to $252.01M (FY2025) — a 279% increase in three years. Operating income of $30.87M (12.2% margin) and 16.1% gross margin. The financials are solid on paper but the +22% move on 371K volume with no catalyst is a thin-float pump pattern. Chinese holding companies listed on U.S. exchanges carry elevated governance and VIE structure risk. Board changes announced June 16 suggest internal restructuring. Recurring scanner name. Avoid the pump — the business may be real but the price action isn't.

FCEL gained +11% but announced a $200M common stock offering (priced at $21 pre-split, upsized from $200M range) just after hours on July 7. The after-hours plunge that followed the offering announcement was significant. FuelCell Energy manufactures molten carbonate fuel cell power plants for industrial and utility applications. TTM revenue of $167.88M (30% YoY growth) but ($30.55M) gross loss — the company can't manufacture fuel cells profitably. Operating loss of ($228M) when including other OpEx. The company has been losing money for decades. The $200M offering is massively dilutive. Bounce today is a dead cat bounce before the dilutive shares hit the market. Avoid.

SUNE gained +13% with no clearly identifiable single catalyst — likely momentum from the broader solar/energy policy tailwind. SUNation Energy is a Long Island, NY residential solar installer with TTM revenue of $66.46M and a healthy 37.2% gross margin ($24.7M). Revenue grew 18% YoY but is volatile (down 29% in FY2023, up 189% in FY2022). The company is a small regional solar installer with no national scale, limited analyst coverage, and exposure to New York solar policy (Net Metering, NY-Sun incentives). The gross margin is solid and the business is real — residential solar installation with maintenance. But nano cap solar installers are subject to policy risk, seasonality, and limited growth runway in a single market. Neutral.

ENVX bounced +12% after sliding from $7 to ~$5 on smartphone battery qualification timeline concerns. Enovix manufactures 100% silicon-anode batteries offering higher energy density than conventional lithium-ion for wearables, smartphones, and EVs. TTM revenue of $34.32M (50% YoY growth) but ($178M) operating loss ($186M total OpEx). Gross margins swung from deeply negative (FY2022-FY2023) to slightly positive ($7.4M gross profit, 21.6% margin) — a meaningful inflection. BofA rates Neutral with a raised PT on smartphone qualification progress. Manufacturing is scaling in Korea. The technology is real and differentiated (silicon anode = higher energy density), but the company is years from profitability and the smartphone qualification timeline remains uncertain. Neutral — real technology at an inflection point.

RKTO surged +35% on this morning's announcement that it was 'accepted into the SpaceXAI API program' and 'added the SpaceXAI API to its AI technology stack.' The press release is classic retail pump bait: Elon-adjacent (SpaceXAI) + AI + space = maximum buzzword density. Reality check: Rocket One has $0 revenue, $11.53M in annual operating expenses ($6.03M SG&A + $5.51M R&D), and an operating loss of ($11.53M). The company has been burning $11-14M per year since at least FY2021 with no revenue to show. $8.4M cash as of June 12. The SpaceXAI API program is likely open to any developer — it's a public API, not an exclusive partnership. Adding an API to your 'tech stack' requires zero commitment or payment. This is a narrative shell pumped by Elon-adjacent buzzwords. Avoid.

DCX gained +19% on 10.8M volume with no identifiable catalyst. Digital Currency X Technology had $0 revenue and $0 gross profit in FY2025 after revenue collapsed from $22.3M (FY2021) to $14.96M (FY2023) to $9.48M (FY2024) to zero. The company previously had negative gross margins in FY2021-FY2024 (selling below cost every year). SG&A of $8.43M on zero revenue means the company is burning cash with no revenue. DCX is essentially a defunct company. +19% on no news in a dead company is pure speculation on a thin-float nano cap. Avoid.

IOTR surged +32% on 8.6M volume with no identifiable news catalyst. The company is an IoT solutions provider with TTM revenue of $12.57M (31% YoY growth), $2.55M gross profit (20.3% margin), and near-breakeven operating income ($0.39M). The financials are actually reasonable — growing revenue, profitable operations, decent margins. But the +32% move on no news, combined with a prior +170% premarket spike in January 2026, follows a pattern of momentum-driven pumps in thin-float Chinese nano caps. The company provides IoT hardware and software solutions but has no analyst coverage and limited transparency. Avoid the pump, not necessarily the business.

BATL gained +19% on a refinanced senior secured credit agreement that lowers borrowing costs, extends maturity to December 2029, and defers principal payments for one year. Battalion is a Permian Basin E&P company founded in 1987. TTM revenue of $125.47M (declining 11.6% YoY) with $24.4M gross profit (19.5% margin). But revenue has collapsed from $359M (FY2021) to $125M — a 65% decline. The updated drilling program (May 28) targets production growth, but the company's trajectory is concerning. The refinancing buys time but doesn't fix the fundamental revenue decline. Oil prices at ~$69/bbl provide no tailwind. Avoid — dying Permian producer buying time through debt restructuring.

PRME gained +8.5% on continued momentum from New Zealand clinical trial clearance for PM577 (Wilson Disease) — the first in vivo prime editing trial for Wilson Disease, with Phase 1/2 initiation expected H2 2026. Prime Medicine's lead candidate PM359 is in Phase 1/2 for Chronic Granulomatous Disease (CGD), with initial data expected 2026. The company's proprietary Prime Editing platform is differentiated from CRISPR-Cas9 — it enables precise gene corrections without double-strand breaks. $3.18M revenue (partnership/collaboration), $210.65M annual operating loss ($154M R&D + $56.5M SG&A). Cash runway into 2026. ~$338M market cap. The platform technology is legitimate but pre-revenue. Neutral — promising science but early-stage.

LUCY surged +24% on Q2 2026 preliminary results showing net sales up 71% YoY to $0.99M (12th consecutive quarter of YoY growth) and a 345-store rollout with FYihealth/FYidoctors optical chain in Canada (Q3 2026 placement). Innovative Eyewear manufactures Bluetooth audio glasses with ChatGPT integration under Lucyd, Lucyd Armor, Reebok, Nautica, and Eddie Bauer brands. TTM revenue of $2.98M (75% growth) with 7.7% gross margin. The company is still deeply unprofitable ($9.3M SG&A on $2.98M revenue) but the growth trajectory and brand licensing strategy are compelling. The 345-store Canadian rollout is the largest single retail expansion to date. Smart glasses are a nascent but growing category — Meta Ray-Ban proved the concept. LUCY is a nano cap play on smart eyewear adoption. Speculative Buy.

EOSE gained +6.5% on a rights offering (record date July 1) to raise capital for zinc battery manufacturing scale-up. Eos Energy manufactures zinc-based battery energy storage systems from Edison, NJ. Revenue surged to $160.71M TTM (726% YoY growth) — but the company has a ($163.73M) gross loss, meaning it sells batteries below cost. SG&A ($88.2M) and R&D ($32.4M) add another $120M in operating expenses. Total operating loss: ($284M). The company is pursuing a rights offering to fund Frontier Power USA deployment. Zinc batteries are a legitimate alternative to lithium for grid storage, but Eos can't manufacture profitably at any scale. The 726% revenue growth is value destruction, not value creation. Avoid.

AMPG gained +11% on continued momentum from insider buying (back-to-back purchases June 22-24) and 149% revenue growth. AmpliTech designs and manufactures RF amplifiers and microwave components for satellite, 5G, and aerospace/defense applications. TTM revenue of $26.95M (up from $10.81M YoY) with 27.5% gross margins. But the company remains unprofitable — SG&A ($12M) and R&D ($2.45M) exceed gross profit ($7.41M). Insider buying is a positive signal. The addressable market (satellite, 5G, defense RF) is growing. At $151M market cap and 5.6x revenue, the valuation is reasonable if the company reaches profitability. Neutral — real business with real growth, but needs to prove it can convert revenue into earnings.

TDIC gained +16% on continued momentum from $2.6M in private placements (June 23: $1.4M Hong Kong placement, June 30: $1.2M Reg S placement). Dreamland is a company offering digital content and technology services with TTM revenue of $54.75M but 11.6% gross margins and ($44.3M) SG&A that wipes out all gross profit. Operating loss is massive. Trading was halted twice in June (volatility pauses). Revenue grew 124% YoY but at 11.6% gross margin, the business model is fundamentally flawed — the company spends $4.44 to generate $1 in SG&A for every $1 in gross profit. Serial diluter with recurring scanner appearances. Avoid.

SKYQ gained +22% as the Foreland refinery production start (scheduled July 1) generated investor interest. Sky Quarry is a Utah oil sands company with a vertically integrated model tying 180M barrels of PR Spring resource to the 5,000 BPD Foreland refinery in Nevada. But TTM revenue of $6.16M is declining 67% YoY, gross margin is negative ($-1.17M), and operating loss is ($8.19M). The company also pivoted to a sustainable aviation fuel (SAF) narrative via partnerships with Southern Energy Renewables and DevvStream. Recurring scanner name — this is the third+ appearance in our scanner. Promising asset (180M barrels) but execution and financials are terrible. Avoid until production actually starts and proves positive cash flow.

TDTH surged +65% on a 240-for-1 share consolidation and CEO conversion of $8M debt into 901M restricted Class B shares, subject to EGM vote July 8. Trident is a Singapore-based digital services company with $160K revenue (declining 65% YoY), $80K gross profit, and ($19.4M) operating loss. SG&A alone is $18.2M — 114x revenue. The 240:1 reverse split is a Nasdaq minimum bid compliance maneuver. The CEO debt-to-equity conversion eliminates $8M in debt but dilutes existing shareholders with 901M new restricted Class B shares. Revenue has collapsed from $1.48M to $160K in two years. This is corporate reanimation, not a turnaround. Avoid.

LHSW surged +186% on 30M volume with no identifiable news catalyst. The company is a Shenzhen, China-based technology provider with $36.5M revenue (FY2025), $9.6M gross profit (26% margin), and $3.03M operating income. Revenue grew from $3.07M to $36.5M in two years — explosive but from a tiny base. The company lists on NASDAQ but is headquartered in Shenzhen with all the governance, transparency, and regulatory risks that entails. No analyst coverage, no identifiable catalyst for the +186% move. StocksToTrade described it as a 'violent intraday spike' drawing momentum traders. +186% on no news in a Chinese nano cap is a pump pattern. Avoid.

SPHL gained +32% on continued momentum from its sustainability pivot — a January 2026 solar partnership for residential housing in Singapore that sent the stock up 500%+ at the time. Springview is a Singapore-based design and construction company with declining revenue ($7.8M, -11% YoY), thin margins (13.7% gross), and ($2.48M) operating loss. The company adopted an equity incentive plan in March 2026 authorizing 400K shares. A trading halt occurred on June 8, 2026 (volatility pause). Singapore construction nano caps are high-risk with limited transparency. The solar narrative is a thin cover for a declining construction business. Avoid.

QTEX gained +17% on continued momentum from a June 2026 quantum computing partnership announcement — the third or fourth time this name has appeared in our scanner this year. QTREX Quantum is a pre-revenue quantum computing company with $290K revenue, zero gross profit, and ($13.6M) annual operating loss. The company has burned cash for years (FY2021-FY2025 all show losses of $11-15M/year) with no revenue growth. Quantum computing is a legitimate long-term technology, but QTEX has no meaningful product, no customers, no IP moat, and no path to profitability. Each 'partnership' or 'collaboration' announcement creates a short-term pump that fades. Avoid.

PEW gained +14% to $2.66 on continued momentum from Q1 results ($25.9M revenue, +11% YoY) and the PEW Logistics launch. GrabAGun is the largest digital firearms marketplace in the U.S., processing FFL transfers through its e-commerce platform. TTM revenue of $99M with 12% gross margins and $106M+ in cash. But the company went from $4.12M operating profit to ($4.36M) operating loss — profitability collapsed as the company invests in logistics. At $2.66 and ~$130M market cap, the stock trades at just 1.2x revenue with more cash than market cap. The firearms market is politically sensitive but structurally growing. Neutral — cheap but needs to prove the logistics investment generates returns.

SEER surged +38% on a perfect storm of catalysts: (1) Radoff-JEC Group submitted a third non-binding buyout proposal at $2.40/share cash plus CVR, now reportedly sweetened to $2.45; (2) Won European patent opposition confirming core proteomics IP; (3) U.S. ITC opened investigation into competitor Nanomics. Seer is a Redwood City proteomics pioneer with $16.6M revenue and $219M in cash (per activist filing). The stock trades below net cash value. But the board rejected all three proposals as 'highly contingent and non-binding,' revenue is flat (-0.9% YoY), and the company burns ~$85M/year on R&D + SG&A. Neutral — the buyout premium is real but the board's resistance and cash burn keep this from being a clear Buy.

SOC dropped yesterday on a $300M convertible notes + $100M equity offering and bounced +19% today. The raise funds the restart of Santa Ynez, a massive offshore California oil field shut since 2015. Sable restarted the pipeline system in March 2026 after a decade-long shutdown. The Santa Ynez unit produced ~25,000 bbl/day pre-shutdown — at current oil prices, that's ~$1.5B annual revenue potential. But SOC has $1B+ in debt, ($467M) operating loss, no current production revenue, and the raise is massively dilutive. California offshore oil is environmentally controversial and politically uncertain. This is a binary bet: if Santa Ynez restarts and produces, the stock re-rates to $20+. If regulatory/political issues block restart, it goes to single digits. Speculative Buy.

EHGO surged +72% on 18.9M volume — the same day it priced a $750K registered direct offering of 750,000 shares at $1.00. Eshallgo is a consumer electronics and smart home products company. Revenue of $14.55M TTM (declining 5.5% YoY) with ($14.9M) operating loss — the company loses money on every dollar of revenue. The $750K offering at $1.00/share (current price $1.55) is dilutive at a below-market price. No identifiable catalyst beyond the offering. +72% on a dilutive raise day is paradoxical — likely momentum/speculation. Avoid.

TC surged +151% on 24.5M volume with no identifiable news catalyst. Token Cat is a NASDAQ-listed company operating in cryptocurrency/digital content services. Revenue of $5.92M in FY2025 with ($34.6M) operating loss. FY2024 had zero revenue. FY2023 had $183M revenue but massive losses — the business model appears to have collapsed. SG&A of $34.6M on $5.9M revenue means the company spends 5.9x revenue on overhead. No analyst coverage, no institutional following. +151% on no news is pure speculation. Avoid.

LHAI surged +188% on lock-up expiration for 8.07M shares and the expected closing of its Mortgage One acquisition (July 1). Linkhome is a Chinese fintech company offering AI-powered mortgage lending and 'Buy Before Sell' programs. Revenue grew to $20.99M but gross margin collapsed to 3.4% ($0.77M gross profit). The company acquired Mortgage One Group to expand AI lending, but the financials show a low-margin lending business in a challenging Chinese real estate market. Chinese nano caps on NASDAQ carry elevated governance and regulatory risk. +188% on lock-up expiry and acquisition closing is classic momentum, not fundamentals. Avoid.

CANF surged +54% on continued momentum from positive Phase 2a results for Namodenoson in advanced pancreatic cancer (reported April 23, 2026). Wainwright analyst has a $65 price target. The company also completed Phase 2 enrollment for Piclidenoson in canine osteoarthritis. Can-Fite's A3 adenosine receptor platform is differentiated — targeting inflammatory and fibrotic diseases via a novel mechanism. But revenue is $410K (declining 40% YoY), ($9.8M) annual loss, and the company is Israeli-based with limited institutional following. The pancreatic cancer data is the real catalyst — if Phase 2b/3 results confirm the signal, this nano cap could re-rate significantly. Speculative Buy.

INTZ surged +36% after announcing the acquisition of managed security service provider VigilAigent from Tego Cyber, adding approximately $3.5M in annual recurring revenue from multi-year contracts. Intrusion Shield is a legitimate cybersecurity platform serving government, law enforcement, and critical infrastructure clients. But the financials are grim: $6.2M TTM revenue (declining), ($10.6M) operating loss, Nasdaq minimum bid deficiency notice (May 13), and Q1 revenue down 50% due to delays in a key U.S. government contract. The VigilAigent acquisition is positive — it doubles ARR — but INTZ still loses $10.6M annually on $6.2M revenue. At under $0.75, Nasdaq delisting risk looms. The cybersecurity product is real, but the business model needs more scale to survive. Neutral.

BTCT surged +55% after closing a $7M private placement (up to $28M with warrants) to fund an 8MW AI computing center in Georgia, and terminating a prior share sale agreement. But the stock tanked on June 26 when the same $28M offering was announced — today is a dead cat bounce on the closing news. BTC Digital is a Singapore-based crypto mining company pivoting to AI compute. Revenue of $14M with a ($9M) net loss and negative gross margins. The $7M upfront proceeds come with up to $21M in additional warrant exercises — more dilution coming. The AI compute narrative is hot, but this is a crypto miner burning cash with a history of diluting shareholders. Avoid.

SVRE surged +137% on a stacked week of catalysts: the $7M VisionWave strategic transaction closed (June 26), a pilot cooperation with RBtec for defense/security applications (signed June 16, reported today), and major insider buying (June 8). SaverOne's RF sensing technology is legitimate — the core distracted driving detection system has been deployed commercially. The defense expansion into RF detection for security applications (perimeter detection, concealed weapon identification) is a logical pivot with a massive TAM. But the financials are concerning: $1.02M revenue (declining), ($29.4M) annual loss, negative gross margin, and 3,298% share dilution YoY. At $138M market cap and 135x sales, SVRE is pricing in defense contract success that hasn't happened yet. The technology is real and the thesis is credible, but the valuation requires significant revenue growth to justify. Speculative Buy.

SAGT surged +24% after CEO Chen Ng purchased 1.5M shares and the company guided 35% revenue growth to $25.8M for FY2026. Sagtec Global is a Kuala Lumpur-based IT services company providing software development, cloud computing, food ordering kiosks, and power bank charging stations. The financials are surprisingly decent: $77.5M revenue, $7.3M net income, 23% operating margin, and $8.66M operating income in FY2025. Revenue grew 49% YoY. But this is a Malaysian nano cap with limited disclosure, a CEO who just pumped the stock with insider buying PR, and a business model (food ordering kiosks, power bank stations) that sounds like a hardware hustle. Neutral — real profits but limited transparency.

TVRD rose +17% on momentum from positive Phase 2 IPF (idiopathic pulmonary fibrosis) data for its lead STAT3 inhibitor, plus a Lucid Capital upgrade to Buy. The company has no revenue (pre-commercial), ($29.5M) annual operating loss, and $19.8M in R&D. But Tvardi's TVT-307 is a differentiated STAT3 pathway inhibitor in a disease with no cure and limited treatment options. If Phase 2 data is confirmed and Phase 3 enrollment begins, this nano cap could re-rate significantly. Binary biotech bet with meaningful upside if the science works. Speculative Buy.

SRFM surged +35% on SurfOS momentum and Palantir AIPCon showcasing, with 100 broker targets and 10 new LOIs cited. But Surf Air Mobility has $109M revenue with ($71.7M) operating loss, 5% gross margins, $41M annual interest expense, and a stock price under $0.50. The SurfOS platform (Palantir-powered broker operating system) is pre-revenue. Canaccord lowered PT to $1.50 from $2.25 in May. The company raised $30M in new capital. At ~$50M market cap with $109M revenue and massive losses, the risk/reward is unattractive. The SurfOS narrative is interesting but unproven. Avoid.

PETS surged +33% after a major investor doubled their stake on June 9 and the company reported Q4/FY2026 earnings showing a 'painful turnaround' with the first sequential Q4 revenue increase since FY2024. But revenue collapsed from $274M to $179M (-35% in two years), operating loss hit ($58.7M), and the company received buyout offers but chose to remain public. Competing against Chewy and Amazon in online pet pharmacy is brutal. The investor doubling down is a vote of confidence, but the business fundamentals are still deteriorating. Neutral — watch for turnaround evidence before committing.

NN, Inc. surged +37% after an investor day presentation outlining 2026 guidance of $460M sales (+$100M JV), $57M adjusted EBITDA (12% margin), and $73M trailing grid/data center revenue. The company is pivoting from declining automotive markets toward data center infrastructure, and recently won new NVIDIA data center awards. Q1 results beat estimates, management raised full-year guidance, and the grid/power infrastructure tailwind is real. At ~$160M market cap, NNBR trades at just 0.35x sales and 2.8x EBITDA guidance — cheap for a company with NVIDIA data center exposure and improving profitability. Bullish.

ILLR surged +57% after announcing a 'strategic treasury asset' providing economic exposure to SpaceX through a SPCX-linked fund structure — essentially copying MicroStrategy's Bitcoin treasury strategy but substituting SpaceX. Days earlier, Triller executed a 1-for-10 reverse split to meet Nasdaq's $1 minimum bid requirement ahead of a June 30 delisting deadline. The financials are catastrophic: $21.6M revenue, ($174.5M) net loss, -$349M shareholder equity, and SG&A of $156M on $21.6M revenue. The company spends $7.22 in overhead for every $1 in revenue. SPCX exposure is not direct SpaceX equity — it's a derivative-linked fund structure with financing secured by the underlying position. This is a deeply insolvent company using a SpaceX narrative to pump its stock while scrambling to avoid Nasdaq delisting. Avoid.

GETY surged +135% after announcing a multi-year display partnership with OpenAI that will surface Getty's licensed image library in ChatGPT search and discovery features. The deal is legitimate and validates Getty's content licensing strategy against AI companies. But Getty carries $2B in debt, $178M in annual interest expense, ($108M) net loss, and a sub-$1 stock price that triggered NYSE compliance issues. The float is extremely thin — the majority of shares are held by the Getty family and private equity sponsors. Short interest is elevated. The +135% move is driven partly by short covering and momentum, not just the OpenAI deal fundamentals. The deal is positive but financial terms are undisclosed, and the debt burden remains crushing. Neutral.

CAST surged +102% on June 18, 2026 — its third 100%+ spike in five days — driven by a DIRECTV distribution partnership announcement. FreeCast is a free streaming aggregator app with $630K in annual revenue, $14M in losses, and a going-concern disclosure. The company has lost money every year since at least 2021, with cumulative losses exceeding $70M. SG&A of $14M on $630K revenue means the company spends 22x what it earns on overhead. The DIRECTV deal is real but no deal economics have been disclosed. At ~$60M market cap, CAST trades at 95x revenue for a company with a going-concern warning. Avoid.

CHAI surged +339% on 57.5M volume with no identifiable new catalyst. The company — formerly operating in a different business — rebranded as 'Core AI Holdings' and announced three AI data center joint ventures (Allianca, Toto Digital, OptiCore) in rapid succession. Revenue jumped to $55.2M in FY2025 but gross profit was negative (-$0.3M), meaning the company loses money on every dollar of revenue. The 20-F filing is delayed. Share dilution hit 249,373% YoY. Net loss of $31.6M. This is a shell company riding the AI narrative with no profitable operations. Avoid.

STI surged +264% on a non-binding MOU to supply pouch cells (potentially $4-6M revenue) and a patent monetization deal with Hilco Global. The company has $100K in TTM revenue, $7.64M in annual losses, and delayed 10-K and quarterly filings with the SEC. Founded June 2023. Zero commercial products. The Hilco patent deal guarantees no specific revenue. The MOU is non-binding. The solid-state battery narrative is hot, but Solidion is a pre-revenue shell with accounting issues, no products, and a stock that has already spiked 264% on headlines. Avoid.

AMSS surged +116% after Good Twin Wine was announced as the #1 organic non-alcoholic wine brand in the U.S. — a category so niche it's essentially meaningless. The stock direct listed at $17 on May 20, crashed to $3.50 in a week, and is now bouncing on a press release. Revenue has collapsed 47% from $33.5M to $17.8M over two years. Gross margins fell from 32% to 21%. The company loses $14.6M annually and just filed an 8-K for a $6.99M Series C convertible preferred raise — dilutive. The non-alc beverage trend is real, but AMASS is a value-destroying brand aggregator with deteriorating fundamentals. Avoid.

CODX surged +30% on the CoMira Saudi JV moving to execution phase and an ESCMID presentation. But Q1 2026 revenue was $146,000. That's not a typo. The company lost $9.1M in the quarter on $146K in revenue — a 62,000% loss-to-revenue ratio. Revenue has collapsed 99.8% from its $298M FY2021 COVID peak. The Saudi manufacturing JV is real but years from generating meaningful revenue. Co-Dx PCR platform needs FDA submission, clinical validation, and commercial scaling — all uncertain. At ~$52M market cap for a company with $720K TTM revenue, CODX is massively overvalued. Avoid.

MetaVia surged +42% after presenting DA-1726 (a GLP-1/glucagon dual agonist for obesity) and vanoglipel (GPR119 agonist for diabetes) data at ADA 2026. Fein reiterated Buy with a $20 PT. The GLP-1 market is a $100B+ opportunity and DA-1726's once-weekly oxyntomodulin analog is differentiated from Wegovy/Zepbound. But: zero revenue, $13.7M annual loss, 139% share dilution, Phase 1 only, and a stock that traded at $1.4M/share pre-split. The $20 PT requires DA-1726 to succeed in Phase 2/3 and compete against Eli Lilly and Novo Nordisk. At $8M market cap, the option value is cheap but the binary risk is extreme. Speculative Buy for risk capital only.

Entravision surged +74% after Q1 2026 earnings showed revenue +114% to $197M and a swing to profitability ($12.4M net income). The story isn't Spanish-language TV and radio anymore — it's ATS (AdTech Services), which grew revenue +204% to $154.6M and now represents 79% of total revenue. Programmatic advertising to mobile app developers is scaling explosively. Operating income of $20.7M is a 427% improvement. The company still pays a $0.05 dividend. At 0.76x TTM revenue with accelerating growth, EVC is one of the cheapest high-growth adtech stories in the market. Bullish.

Cue Biopharma surged +93% after announcing a $30M private placement and receiving a $7.5M milestone payment for CUE-401/CUE-501 preclinical programs. The company is a clinical-stage biotech developing T-cell engagers for cancer and autoimmune disease, partnered with Bristol Myers Squibb on CUE-102. Revenue of $27.5M in FY2025 is entirely milestone/collaboration income — zero product sales. The company burns $37.7M annually on R&D alone. The $30M financing extends runway but the 3.22M share count has grown 68% YoY through dilution. At $92M market cap, CUE is pricing in clinical success that hasn't happened yet. Neutral.

SNBR surged +27% ahead of Q1 earnings (April 29) as the market prices in a potential floor. Revenue declined 16% to $1.41B in FY2025 with a $132M net loss. The smart bed category pioneer is losing market share to cheaper foam mattresses and DTC brands. Analyst consensus is Hold with a $4.50 price target. CEO has guided for Q2 stabilization. At $64M market cap and $22.9M shares, the stock is a binary pre-earnings bet. Neutral — the fundamentals are deteriorating but the downside at $2.80 may be limited if Q1 shows stabilization.

SEGG surged +27% on the launch of Sports.com Predict, a sports predictions platform targeting the 2026 FIFA World Cup. The company owns Sports.com, Concerts.com, TicketStub.com, and Lottery.com — valuable domain names attached to a business with $0.9M TTM revenue, ($20.8M) net loss, 12 employees, and 284% share dilution YoY. Revenue has collapsed 84% in the last year. The NASDAQ has issued a delisting notice for late 10-K filing. This is a domain-name hype stock with no revenue model that works. Avoid.

BBBY surged +30% after Q1 2026 earnings showed the first revenue growth in 19 quarters (+6.9% to $247.8M) with net loss narrowing to $16.4M and $163M cash. This is Beyond Inc. (formerly Overstock) that acquired the Bed Bath & Beyond IP out of bankruptcy and is rebuilding the brand online + physical stores. CEO Marcus Lemonis targets 6-7% EBITDA margins. Revenue is still 62% below pre-bankruptcy levels, the company burns $61M/year, and gross margins are a thin 23.9%. But the turnaround thesis is showing early signs of life. Speculative Buy for risk capital.

Aterian announced a definitive agreement to sell its Marquee Brand Portfolio for $18M — 2.5x the company's $7M market cap. Combined with $7.6M in existing cash, total distributable assets could reach $25M+ against a $7M valuation. Revenue has collapsed 72% from peak ($248M → $69M), but the brand sale marks the start of a structured wind-down. The strategic alternatives review is delivering concrete results. Key risks: remaining debt, wind-down costs, and whether the $18M is subject to adjustments that reduce proceeds. Speculative but the math is compelling.

Allbirds agreed to sell all assets to American Exchange Group (AXNY) for $39M and dissolve the company. Distributions expected Q3 2026. At the current ~$2.51 price, the implied value per share depends entirely on residual cash, tax assets (NOLs), and wind-down costs. William Blair estimates ~$5.70/share fair value including NOLs. But the $39M sale is only ~$0.44/share before expenses. This is a liquidation arb — not an operating investment. Neutral.

RCT is up +122.81% pre-market after signing a $30M, 5-year Saudi Arabia licensing deal to deploy its RAID AI engine across a $68B FMCG market. This is RedCloud's second major JV in four months, bringing combined contracted JV infrastructure revenue to $80M — not bad for a stock that was trading at $0.68 yesterday.

OMEX surged +144% on a $1B merger with AOMC to create American Ocean Minerals Corporation — a deep-sea critical minerals platform targeting polymetallic nodules for battery metals and phosphate for fertilizer. 30+ years of offshore operating experience. Cook Islands nodule JV with a $4.7B JORC resource estimate. Trump pro-mining executive order tailwind. Binary bet on seafloor mining. Speculative only.

ADVB surged +63% on April 7, 2026 with no identifiable company-specific news, press release, or filing. This is a pre-revenue Taiwan-based microfluidic biochip company with 1.36M shares, 31 employees, zero revenue, and TTM 'net income' of $4.39M that is entirely driven by a one-time $7.41M non-operating income item. Operating losses are ($2.9M). FCF is ($6.11M). The stock crashed from a 52-week high of $75.40 to $3.61 before today's pop. Avoid.

TMD Energy surged +57% on pure macro oil momentum. The valuation anomaly is real: $607M TTM revenue at a $25M market cap (0.04x P/S). But it's a marine fuel bunkering company with 2.4% gross margins, net losses, negative FCF, and no pricing power. Revenue is throughput, not value creation.

CYCN surged +185% on an all-stock merger with Korsana Biosciences, a private neurodegenerative disease company targeting amyloid beta for Alzheimer's. $380M concurrent private financing funds operations through 2029 with clinical data readouts in 2027. Binary bet on neurodegeneration — well-funded but pre-clinical.

nCino crushed Q4 FY2026 earnings — EPS $0.37 vs $0.21 expected, ACV +17% YoY, $100M buyback launched. FY2027 guidance: $639-643M revenue, $132-137M FCF. Cloud banking SaaS at profitability inflection with 112% net retention. Underfollowed fintech at 12.8x forward FCF.

Target Hospitality surged +35% after landing a $550M+ multi-year contract with a top-5 hyperscaler to build a 4,000-person modular accommodations campus for North Texas data center workers. Second hyperscaler deal in 8 months. Zero net debt, $183M liquidity. The pivot from oilfield housing to AI infrastructure enabler is signed paper now — not just narrative.

BFRG surged 126%+ on a 'top-5 pharma deal' for MDD target identification. The 8-K reveals it's actually a Feasibility Agreement — a paid pilot, not a commercial contract. $120K annual revenue, $6.6M burn, ~3.5 months runway, dual Nasdaq delisting risks, 9 employees. Avoid.

Sound Group surged +32% on 53% revenue growth and a return to profitability. But the Big Four auditor quit over cash disputes, RMB 90.7M vanished, and US investors own a Cayman shell. The numbers look great on paper — you just can't trust them.

Hong Kong digital marketing firm with 7 employees, revenue cut in half, and mounting losses. Recent 1-for-16 reverse split signals desperation to maintain Nasdaq listing. Fundamental deterioration and micro-cap risks make this uninvestable.

Community oncology leader hit first profitable quarter (Adj. EBITDA) in Q4 2025. Revenue +28% to $503M with expanding capitated contracts. 2026 guidance targets $630-650M revenue and positive Adj. EBITDA.

Clinical-stage biotech with Phase 3 itolizumab data and potential BLA submission in H1 2026. $50M raise extends runway to 2027, but no approved products and continued cash burn make this a binary outcome play.

Polar Power is up 12.9% on 20M+ shares in pre-market trading, but there's no specific catalyst. The company manufactures DC power systems for telecom, military, and renewable applications, but has no earnings news and faces Nasdaq delisting risk. This is speculation, not investment.

Codexis just delivered a Q4 beat with 81% revenue growth, guided $72-76M for 2026, and has $78M cash through 2027. The ECO Synthesis platform is scaling from 100-gram to half-kilogram production, and a Merck deal added $38M in non-dilutive capital. This is an RNA manufacturing thesis.

Tilly's just shocked the market with a Q4 beat that sent shares up 81% overnight. Same-store sales jumped 10%, gross margins are expanding, and management sees a clear path to annual profitability. This isn't your typical mall retailer story.

Clinical-stage biotech trading at 1x cash with three differentiated platforms — Kv7 epilepsy, extracellular protein degraders, and ADCs — all hitting pivotal data in H2 2026. Opakalim's 40x therapeutic index edge in epilepsy could be worth $2-3B alone.

EON Resources operates 1,000+ bbl/day from 20,000 Permian Basin acres with a $300M Virtus farmout underway, $37M in debt retired, and 60% of 2026 production hedged at $60+. The market is pricing this at $18M. The NPV-10 alone is >$95M.

TPET spiked 318% in a week on Alberta well news. The problem: those wells produce 30-40 barrels per day, and the company lost $2.71M on $398K in quarterly revenue. The math says fade this move.

Spanish AI-solar storage company with a $53M signed industrial backlog trading at an $18.5M market cap. Revenue growing, losses narrowing 51% — but Nasdaq compliance risk is real and must be watched.

Moolec surged 90% on validated 45% GLA concentration from engineered safflower at commercial scale. The science is real — 1,100 acres, standard crushing infrastructure, genuinely differentiated molecular farming. But a $7M market cap, going concern language, and a June 2026 Nasdaq deadline make this a watch-and-wait.

CDIO is up +25% pre-market on heavy volume as momentum continues from the company's Feb 19 investor call showcasing AI-driven coronary heart disease tests with preliminary CMS reimbursement approval in hand. At a $9.5M market cap, the risk/reward is asymmetric — if Medicare reimbursement finalizes, this company is worth multiples of today's price.

Searchlight Capital and Abry Partners are acquiring KORE at $9.25/share — a 691% premium to the December 2024 unaffected price — validating that this pure-play IoT hyperscaler was trading at a fraction of its strategic value.

TheRealReal crushed Q4 2025 estimates — $194M revenue (+18% YoY), non-GAAP EPS of $0.06 vs. $0.04 consensus — delivering the first full year of positive adjusted EBITDA in company history. The market is waking up to the fact that luxury resale has a dominant, defensible platform, and REAL just proved it can make money.

RBNE is up +6.5% pre-market as momentum builds ahead of Q4 earnings — the first quarter to fully reflect its three-vessel LPG and tanker fleet. The real story: a debt-free operator with $5.5M in locked 2026 charters trading at 22 cents on the dollar of net asset value.

LASE is up +6.8% in pre-market after landing a repeat CMS Laser marking order from a fiber optic manufacturer with 20+ installed systems — validating enterprise traction despite a turbulent year that included a financial restatement, securities investigations, and a dilutive $5M equity raise.

GCT surged +32.4% on record Q4 earnings — EPS of $1.04 crushed estimates by 40.5%. At 13x trailing earnings with zero debt and $417M cash, this B2B large-parcel marketplace is the most undervalued profitable small-cap we've covered.

DNUT surged +28.6% on 19.1M shares — 7-9x average volume — after Q4 2025 adjusted EPS of $0.09 demolished the $0.03 consensus by 200%. Adjusted EBITDA margin expanded 280 basis points to 14.2% and free cash flow turned positive at $27.9 million. After a brutal year dominated by the McDonald's partnership collapse, Krispy Kreme's Q4 is the first hard evidence the turnaround is real.

Acadia Healthcare trades at a steep discount to intrinsic value as DOJ/SEC investigations weigh on sentiment, but record $3.2B revenue and growing behavioral health demand create an asymmetric risk/reward setup.

Clinical-stage biopharma focused on inflammatory diseases surged 20.5% in pre-market on momentum from recent positive mechanism-of-action data for lead drug rademikibart. Phase 1b IV data expected Q1 2026, Phase 2 Seabreeze STAT readouts mid-2026. Cash runway into 2027 provides cushion through catalysts.

ANPA provides financial printing and corporate services in Hong Kong with nascent Web3 ambitions. Despite recent volatility-driven gains, the company's extreme P/E ratio of ≈5,842, declining earnings, and small scale warrant caution.

Autonomous sidewalk delivery robot maker surged 67.5% in pre-market after announcing Q4 earnings scheduled for March 11. With 2,000 robots deployed via Uber Eats and DoorDash partnerships, 10x revenue growth expected in 2026. The Physical AI thesis is driving momentum.

Nano-cap security robotics company surged 20.2% in pre-market, building on 43% gains from last week's $5M share buyback announcement. Trading below $1 with Nasdaq compliance deadline June 2026, the company is expanding AI/robotics into Hong Kong, Singapore, and Taiwan while pursuing acquisitions.

Palvella's QTORIN rapamycin platform shows compelling Phase 2 data in rare skin diseases with zero FDA-approved treatments, positioning the company for potential accelerated approval pathways.

BNAI surged over 80% after terminating a $50M equity purchase agreement, signaling management's confidence and removing dilution overhang. The conversational AI company serves automotive, healthcare, and financial services verticals.

Global turbocharging leader surged 12.0% in pre-market after Q4 2025 earnings beat estimates ($0.42 vs $0.37 expected). Despite a -7.3% post-earnings sell-off last week, fundamentals remain strong: $3.58B revenue, $510M adjusted EBIT, $403M free cash flow, and 8% share reduction in 2025. New $250M buyback authorized for 2026. The dip offers an attractive entry point for a quality industrial with electrification upside.

Once-promising drive-thru voice AI company is essentially defunct, trading at $0.0001 per share with a ≈$200 market cap. Delisted from Nasdaq and now on OTC Pink Sheets, the company faces severe liquidity crisis and potential bankruptcy. The 16.5% pre-market move has no fundamental meaning—this is a zombie stock.

Unisys beat profitability guidance, slashed its pension deficit by $300M, and holds $414M in cash — yet trades at just 0.09x revenue. A turnaround story with real catalysts.

Rigetti's modular chiplet architecture and international expansion position it as a key quantum infrastructure player, with a $5.48B valuation reflecting both promise and volatility.

Sigma Lithium operates one of the largest hard-rock lithium projects in the Americas but faces severe margin compression. A speculative bet on lithium price recovery with meaningful operational leverage.

Singapore-based health tech company surged 12.9% in pre-market following expansion into stem cell therapy and regenerative medicine. The company recently opened a clinic in Shenzhen and secured a Malaysia direct selling license for its longevity products. While the longevity market is growing, EUDA's business model combines direct selling, clinic operations, and digital health—a complex structure that has yet to demonstrate profitability.

Nano-cap furniture company surged 13.0% in pre-market after announcing a $5.66M investment in a fund holding SpaceX shares. The company recently raised $9M through a public offering, with most proceeds going toward this speculative SpaceX exposure. While the SpaceX brand attracts attention, this represents a radical strategic pivot from a furniture business with minimal revenue and questionable fundamentals.

Vir's infectious disease pipeline trades at a fraction of analyst price targets, with $68.5M in 2025 revenue and programs targeting hepatitis delta, influenza, and novel antibody approaches.

D-Wave has achieved what competitors haven't: real commercial revenue from production quantum workloads, with 100+ organizations actively using its systems and 100% YoY revenue growth.

GBIO announced a 90% workforce reduction and strategic review as it struggles to extend its cash runway, raising significant concerns about the company's ability to continue as a going concern.

GANX reported positive Phase 1b results for GT-02287 in Parkinson's disease, showing first-ever reduction in GCase substrate in CSF, validating the drug's mechanism of action.

Trading at $1.95 with a $10.6M market cap and analyst targets of $13, Edesa offers 760% potential upside if Phase 3 programs in ARDS and dermatitis succeed.

Claritev (formerly MultiPlan) delivered turnaround 2025 results with narrowing losses and $25B in identified medical cost savings, but significant debt and competitive pressures warrant a cautious stance.

Clarivate reported Q4 2025 earnings beating expectations while exploring a potential sale of its Life Sciences segment, but the stock remains pressured by debt concerns and strategic uncertainty.

A $7-10M market cap bitcoin miner doing $7.4M in LTM revenue with sub-$0.04/kWh power costs, two Tennessee facilities, and operating profit up 207% YoY. Trades below book value. The catch: $94K cash and a $3M loan at 12%.

KNRX surged 245% on an 'agentic AI' API launch, but underneath the buzzword sits $0.2M cash, $8.2M debt, shrinking revenue, and 2-3 weeks of runway. We break down why the narrative doesn't match the balance sheet.

Rackspace surged 229% after announcing a Palantir partnership to deploy managed AI for regulated enterprises. At 0.12x trailing P/S with $2.5B in debt, this is either the most credible turnaround catalyst since the re-IPO or a dead cat bounce on a hail mary press release.

A $127M micro-cap with $65K in annual revenue just spiked 41% because its quantum-engineered silicon film may solve the biggest manufacturing challenge in 2nm Gate-All-Around chips. The science is real. The financials are terrifying. Here's why that might not matter.

A $168M market cap company holding 1,000 BTC (≈$89M) and building the first retail tokenized deposit platform with Uphold and Vast Bank. CEO Greg Kidd was first money into Twitter, Square, Coinbase, Ripple, and Solana. At $0.42, you're getting the deposit business for free.

$14.9B in revenue last year — tripled YoY — yet the stock trades at 8x earnings because of an auditor change and a DOJ inquiry. We dug into the filings to separate the governance noise from the business reality.

A $25M market cap company with a SaaS product growing 45% YoY at 72% gross margins — and zero analyst coverage. Their DataV IoT platform is quietly replacing legacy device management across industrial customers.

Uranium spot hit $90/lb and Ur-Energy produces at $28/lb. That's a 61% gross margin on a commodity with a structural supply deficit. Every $10/lb move in uranium adds $6M to their EBITDA — and most analysts expect $100+ by 2027.

For every barrel of Permian oil, 4-6 barrels of water come up — and disposing of it is legally required. Aris runs 1,500 miles of pipeline handling 1.2M barrels/day on 85% take-or-pay contracts. It's a regulated utility disguised as an oilfield services stock, trading at 8x EBITDA.

Down 85% from its 2021 peak, BioAtla trades at $35M enterprise value — less than zero after you back out cash. Two new clinical programs enter readouts in 2026. If either works, you're looking at a 3-5x. If not, you still have $2.20/share in cash.

Enterprise value: $7M. Target market: $5B+. Liminal's first-in-class OXER1 inhibitor for pulmonary fibrosis has orphan drug status and 2.7 years of cash runway — no dilution needed to reach Phase 2 data. The risk/reward math at this valuation is hard to ignore.